Randomised, Double-Blind, Placebo-Controlled, Phase IIa Study in Healthy Volunteers to Evaluate the Protective Efficacy and Safety of CR8020 in an Influenza Challenge Model
Phase of Trial: Phase II
Latest Information Update: 15 Apr 2019
Price : $35 *
At a glance
- Drugs CR 8020 (Primary)
- Indications Influenza A virus infections
- Focus Pharmacokinetics
- Sponsors Crucell Holland B.V.
- 03 Mar 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Oct 2013 New source identified and integrated (European Clinical Trials Database: EudraCT2013-002185-39).
- 12 Sep 2013 New trial record